As activist investor William Ackman, a thorn in Zoetis' side for two years, reported that he'd sold off his stake, the animal health giant reported…

Analysts zeroed in on one main question Monday on the company's earnings call: Is the floundering drugmaker, which just sent its CEO packing last week,…

Regeneron expects Eylea to grow this year at a rate well below Wall Street expectations. But don't ask CEO Len Schleifer to explain.

GlaxoSmithKline CEO Andrew Witty finally laid out just how much damage he expects Advair knockoffs to do this year.

CEO John Milligan was asked to ponder his $30 billion in 2016 revenue—and answer this key question: Can you "grow company without an acquisition?”

The same day that the company showed CEO Erez Vigodman the door, the drugmaker was said to be under investigation by Israeli police for bribing foreign…

As it gets ready to announce earnings after the market closes today, Gilead is trading on Wall Street at less than seven times what analysts estimate it will…

It’s no wonder AZ pushed so hard to protect blockbuster Crestor from generic competition: Its newer meds aren’t bringing in enough cash.

Novo Nordisk was already worried about the U.S., what with stepped-up competition from new rivals and hardball pricing tactics by payers. But it’s even more…

Financials